title: Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.
abstract: BACKGROUND
  Psychiatric comorbidity can adversely affect opioid dependence treatment outcomes. While the prevalence of psychiatric comorbidity among patients seeking methadone maintenance treatment has been documented, the extent to which these findings extend to patients seeking primary care office-based buprenorphine/naloxone treatment is unclear.
  
  
  OBJECTIVE
  To determine the prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment, via cross sectional survey.
  
  
  METHODS
  237 consecutive patients seeking primary care office-based buprenorphine/naloxone treatment were evaluated using modules from the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Current (past 30 days) and past diagnoses were cataloged separately.
  
  
  RESULTS
  Patients ranged in age from 18 to 62 years old (M=33.9, SD=9.9); 173 (73%) were men; 197 (83%) were white. Major depression was the most prevalent mood disorder (19% current, 24% past). A minority of patients met criteria for current dysthymia (6%), past mania (1%), or past hypomania (2%). While 37 patients (16%) met criteria for current abuse of or dependence on at least one non-opioid substance (7% cocaine, 4% alcohol, 4% cannabis, 2% sedatives, 0.4% stimulants, 0.4% polydrug), 168 patients (70%) percent met criteria for past abuse of or dependence on at least one non-opioid substance (43% alcohol, 38% cannabis, 30% cocaine, 9% sedatives, 8% hallucinogens, 4% stimulants, 1% polydrug, and 0.4% other substances).
  
  
  CONCLUSIONS
  Mood and substance use comorbidity is prevalent among patients seeking primary care office-based buprenorphine/naloxone treatment. The findings support the need for clinicians to assess and address these conditions.
authors: APT Foundation, 495 Congress Avenue, New Haven, CT 06519, United States.
authors: Jonathan D
authors: JD
authors: Savant
authors: Declan T
authors: DT
authors: Barry
authors: Christopher J
authors: CJ
authors: Cutter
authors: Michelle T
authors: MT
authors: Joy
authors: An
authors: A
authors: Dinh
authors: Richard S
authors: RS
authors: Schottenfeld
authors: David A
authors: DA
authors: Fiellin
mesh_terms: D000293:Adolescent; D000328:Adult; D002047:Buprenorphine / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D009270:Naloxone / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D015995:Prevalence; D011320:Primary Health Care / Q000639:trends; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D055815:Young Adult
chemical_list: D009270:Naloxone; D002047:Buprenorphine